Systematic review of 33 studies (970 patients; 13 neoadjuvant meta-analysed): disitamab vedotin-containing neoadjuvant regimens in localised urothelial carcinoma gave a pooled pCR rate of 48%. HER2 not clearly linked to response; grade ≥3 AEs ≤35%; no trial was blinded.
Meta-analysisn = 970
Suleja et al. Efficacy of HER2-targeted therapies in localized urothelial carcinoma: a systematic review and meta-analysis